SLU-PP-332

Study · 2026

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential

Rationale Estrogen-related receptor (ERR) agonists such as the drug candidates SLU-PP-332 and SLU-PP-915 are currently being investigated as exercise mimetics, given their ability to trigger human physiological processes similar to those initiated by actual physical activity.

Study · 2026

Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling

Estrogen-related receptors (ERRs) are master regulators of mitochondrial metabolism and exercise-responsive transcription, yet only a limited number of synthetic agonists with suitable potency and drug-like properties have been reported.

Study · 2026

Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes

Exercise mimetics mimic physical activity and prevent development and progression of chronic metabolic diseases, including obesity and Type 2 diabetes. The World Anti-Doping Agency (WADA) prohibits the use of exercise mimetics and metabolic modulators in sports.

review · 2026

[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]

Physical inactivity contributes to the development of chronic diseases. Activation of orphan nuclear receptors estrogen-related receptors (ERRα/β/γ) has emerged as a molecular strategy to mimic exercise-induced benefits.

Study · 2026

An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity

Estrogen receptor-related receptors (ERRα, ERRβ, and ERRγ) are orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle.

review · 2026

Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators